Circular RNA Generation Technology Market Report – Research, Industry Analysis Reports and Market Demands

Global Circular RNA Generation Technology Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

2 Company Profiles

3 Market Competition, by Players

3.1 Global Circular RNA Generation Technology Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
- 3.2.1 Market Share of Circular RNA Generation Technology by Company Revenue
- 3.2.2 Top 3 Circular RNA Generation Technology Players Market Share in 2025
- 3.2.3 Top 6 Circular RNA Generation Technology Players Market Share in 2025
3.3 Circular RNA Generation Technology Market: Overall Company Footprint Analysis
- 3.3.1 Circular RNA Generation Technology Market: Region Footprint
- 3.3.2 Circular RNA Generation Technology Market: Company Product Type Footprint
- 3.3.3 Circular RNA Generation Technology Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

4.1 Global Circular RNA Generation Technology Consumption Value and Market Share by Type (2021-2026)
4.2 Global Circular RNA Generation Technology Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

5.1 Global Circular RNA Generation Technology Consumption Value Market Share by Application (2021-2026)
5.2 Global Circular RNA Generation Technology Market Forecast by Application (2027-2032)

6 North America

6.1 North America Circular RNA Generation Technology Consumption Value by Type (2021-2032)
6.2 North America Circular RNA Generation Technology Market Size by Application (2021-2032)
6.3 North America Circular RNA Generation Technology Market Size by Country
- 6.3.1 North America Circular RNA Generation Technology Consumption Value by Country (2021-2032)
- 6.3.2 United States Circular RNA Generation Technology Market Size and Forecast (2021-2032)
- 6.3.3 Canada Circular RNA Generation Technology Market Size and Forecast (2021-2032)
- 6.3.4 Mexico Circular RNA Generation Technology Market Size and Forecast (2021-2032)

7 Europe

7.1 Europe Circular RNA Generation Technology Consumption Value by Type (2021-2032)
7.2 Europe Circular RNA Generation Technology Consumption Value by Application (2021-2032)
7.3 Europe Circular RNA Generation Technology Market Size by Country
- 7.3.1 Europe Circular RNA Generation Technology Consumption Value by Country (2021-2032)
- 7.3.2 Germany Circular RNA Generation Technology Market Size and Forecast (2021-2032)
- 7.3.3 France Circular RNA Generation Technology Market Size and Forecast (2021-2032)
- 7.3.4 United Kingdom Circular RNA Generation Technology Market Size and Forecast (2021-2032)
- 7.3.5 Russia Circular RNA Generation Technology Market Size and Forecast (2021-2032)
- 7.3.6 Italy Circular RNA Generation Technology Market Size and Forecast (2021-2032)

8 Asia-Pacific

8.1 Asia-Pacific Circular RNA Generation Technology Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Circular RNA Generation Technology Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Circular RNA Generation Technology Market Size by Region
- 8.3.1 Asia-Pacific Circular RNA Generation Technology Consumption Value by Region (2021-2032)
- 8.3.2 China Circular RNA Generation Technology Market Size and Forecast (2021-2032)
- 8.3.3 Japan Circular RNA Generation Technology Market Size and Forecast (2021-2032)
- 8.3.4 South Korea Circular RNA Generation Technology Market Size and Forecast (2021-2032)
- 8.3.5 India Circular RNA Generation Technology Market Size and Forecast (2021-2032)
- 8.3.6 Southeast Asia Circular RNA Generation Technology Market Size and Forecast (2021-2032)
- 8.3.7 Australia Circular RNA Generation Technology Market Size and Forecast (2021-2032)

9 South America

9.1 South America Circular RNA Generation Technology Consumption Value by Type (2021-2032)
9.2 South America Circular RNA Generation Technology Consumption Value by Application (2021-2032)
9.3 South America Circular RNA Generation Technology Market Size by Country
- 9.3.1 South America Circular RNA Generation Technology Consumption Value by Country (2021-2032)
- 9.3.2 Brazil Circular RNA Generation Technology Market Size and Forecast (2021-2032)
- 9.3.3 Argentina Circular RNA Generation Technology Market Size and Forecast (2021-2032)

10 Middle East & Africa

10.1 Middle East & Africa Circular RNA Generation Technology Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Circular RNA Generation Technology Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Circular RNA Generation Technology Market Size by Country
- 10.3.1 Middle East & Africa Circular RNA Generation Technology Consumption Value by Country (2021-2032)
- 10.3.2 Turkey Circular RNA Generation Technology Market Size and Forecast (2021-2032)
- 10.3.3 Saudi Arabia Circular RNA Generation Technology Market Size and Forecast (2021-2032)
- 10.3.4 UAE Circular RNA Generation Technology Market Size and Forecast (2021-2032)

11 Market Dynamics

11.1 Circular RNA Generation Technology Market Drivers
11.2 Circular RNA Generation Technology Market Restraints
11.3 Circular RNA Generation Technology Trends Analysis
11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

12.1 Circular RNA Generation Technology Industry Chain
12.2 Circular RNA Generation Technology Upstream Analysis
12.3 Circular RNA Generation Technology Midstream Analysis
12.4 Circular RNA Generation Technology Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology
14.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global Circular RNA Generation Technology market size was valued at US$ 99 million in 2025 and is forecast to a readjusted size of US$ 543 million by 2032 with a CAGR of 27.1% during review period.
Circular RNA generation technology comprises the methods and process systems used to produce covalently closed circular RNA through sequence design, DNA template construction, in vitro transcription, ribozyme-mediated self-splicing, enzymatic ligation, intracellular splicing, or vector-mediated expression. A complete manufacturing workflow generally includes precursor RNA design, transcription, circularization, removal of residual linear RNA and double-stranded RNA impurities, chromatographic purification, concentration and buffer exchange, structural confirmation, purity testing, expression activity evaluation, and delivery formulation development. Upstream inputs mainly include nucleotide triphosphates, modified nucleosides, DNA and plasmid templates, RNA polymerases, T4 RNA ligases, ribozyme elements, nucleases, buffers, chromatography media, ultrafiltration consumables, single-use bioprocessing materials, analytical reagents, and lipid nanoparticle materials. Downstream customers include RNA drug developers, vaccine companies, gene and cell therapy companies, pharmaceutical companies, CRO/CDMO providers, research institutes, and hospital research centers. The industry's gross margin in 2025 is estimated at approximately 45%–65%.
The circular RNA generation technology market is currently transitioning from a research-tool market into an enabling infrastructure market for RNA drug development. Research-grade custom synthesis, vector construction, and circularization kits continue to represent the basic demand base, while faster growth is occurring in process development, impurity control, analytical method establishment, and GMP manufacturing. Suppliers can generally be divided into three groups: therapeutic developers with proprietary circularization platforms, life-science companies providing research-grade synthesis and kits, and RNA CRO/CDMO companies capable of producing clinical-grade drug substance and formulated products. The United States and China are currently the most active supply regions. Chinese companies have established a relatively broad presence in custom synthesis, process services, and integrated manufacturing, while U.S. companies are more active in proprietary platforms, technology licensing, and therapeutic translation.
Future technology development will shift from maximizing circularization yield alone toward the combined optimization of product integrity, scarless ligation, sequence flexibility, long-transcript compatibility, and manufacturing reproducibility. Conventional PIE approaches have a relatively mature research foundation, but may introduce residual foreign sequences and constrain some sequence designs. Enzymatic ligation approaches can provide more flexible or scarless products, but impose greater requirements on terminal structure, splint design, and enzyme cost. New intact-intron self-splicing, nickless circularization, and integrated circularization-purification technologies are emerging and may reduce impurity burdens and downstream purification complexity. In vitro and intracellular generation routes are expected to coexist, with the former offering better manufacturing control and the latter supporting sustained expression in gene therapy and in vivo cell-reprogramming applications.
Market growth is being driven by the development of next-generation RNA drugs, therapeutic vaccines, in vivo cell therapies, protein-replacement therapies, and genetic medicines. Once circular RNA programs advance into clinical development, demand expands beyond basic RNA synthesis to include high-purity drug substance, residual linear RNA and double-stranded RNA testing, structural characterization, translation-efficiency testing, aseptic production, and regulatory documentation. This substantially increases the value of each project. Downstream developers are also increasingly outsourcing sequence design, template preparation, circularization, purification, analytics, and LNP formulation to integrated suppliers in order to reduce technology-transfer risks and accelerate regulatory submissions. Entry by large pharmaceutical companies and expansion by specialist CDMOs are expected to support more standardized technical and supply-chain practices.
The main barriers are the lack of harmonized evaluation standards across circularization methods and the fact that a high circularization rate does not necessarily result in high purity, strong expression, or low immunogenicity. Uncircularized precursors, mis-ligated products, residual linear RNA, double-stranded RNA, truncated transcripts, and residual DNA can all affect safety and biological activity, placing substantial demands on purification and analytical methods. Long-sequence circularization, batch reproducibility, manufacturing scale-up, enzyme costs, and limited regulatory standards remain major industrialization challenges. The patent landscape is also complex, with overlapping claims covering PIE systems, ligase methods, translation elements, purification processes, and delivery technologies, creating uncertainty around freedom to operate and commercial licensing.
This report is a detailed and comprehensive analysis for global Circular RNA Generation Technology market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Circular RNA Generation Technology market size and forecasts, in consumption value ($ Million), 2021-2032
Global Circular RNA Generation Technology market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Circular RNA Generation Technology market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Circular RNA Generation Technology market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Circular RNA Generation Technology
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Circular RNA Generation Technology market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GenScript Biotech Corporation, Guangzhou Geneseed Biotech, uBriGene Biosciences, Yaohai Bio-Pharma, Creative Biogene, SBS Genetech, Orna Therapeutics, RiboX Therapeutics, Sail Biomedicines, Shanghai CirCode Biomed, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Circular RNA Generation Technology market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
In Vitro Generation
Intracellular Generation
Market segment by Circularization Method
Ribozyme-Mediated Circularization
Enzymatic Ligation
Other
Market segment by Ribozyme Route
Group I Intron-Based
Group II Intron-Based
Other
Market segment by Application
Pharmaceutical and Biotechnology Companies
CRO and CDMO Companies
Other
Market segment by players, this report covers
GenScript Biotech Corporation
Guangzhou Geneseed Biotech
uBriGene Biosciences
Yaohai Bio-Pharma
Creative Biogene
SBS Genetech
Orna Therapeutics
RiboX Therapeutics
Sail Biomedicines
Shanghai CirCode Biomed
Therorna
Circio Holding
Chimerna Therapeutics
Rznomics
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Circular RNA Generation Technology product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Circular RNA Generation Technology, with revenue, gross margin, and global market share of Circular RNA Generation Technology from 2021 to 2026.
Chapter 3, the Circular RNA Generation Technology competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Circular RNA Generation Technology market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Circular RNA Generation Technology.
Chapter 13, to describe Circular RNA Generation Technology research findings and conclusion.

Buy now